Theratechnologies Inc. (TH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theratechnologies Inc. (TH) has a cash flow conversion efficiency ratio of -0.095x as of May 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$2.66 Million ≈ $1.92 Million USD) by net assets (CA$-27.92 Million ≈ $-20.20 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Theratechnologies Inc. - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Theratechnologies Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Theratechnologies Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Theratechnologies Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theratechnologies Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silver X Mining Corp
V:AGX
|
0.051x |
|
Formuepleje Limittellus
CO:FPILIM
|
N/A |
|
KB Star REIT Co. Ltd.
KO:432320
|
0.006x |
|
EQL PHARMA AB
F:7JK
|
0.050x |
|
Cardiol Therapeutics Inc Class A
TO:CRDL
|
-0.292x |
|
SV Investment Corporation
KQ:289080
|
-0.034x |
|
Sahamitr Pressure Container Public Company Limited
BK:SMPC
|
0.131x |
|
TGE Value Creative Solutions Corp
NYSE:BEBE
|
0.019x |
Annual Cash Flow Conversion Efficiency for Theratechnologies Inc. (1996–2024)
The table below shows the annual cash flow conversion efficiency of Theratechnologies Inc. from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see TH market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-11-30 | CA$-25.27 Million ≈ $-18.28 Million |
CA$2.38 Million ≈ $1.72 Million |
-0.094x | -134.60% |
| 2023-11-30 | CA$-20.87 Million ≈ $-15.10 Million |
CA$-5.68 Million ≈ $-4.11 Million |
0.272x | -58.20% |
| 2022-11-30 | CA$-22.57 Million ≈ $-16.33 Million |
CA$-14.69 Million ≈ $-10.63 Million |
0.651x | +179.85% |
| 2021-11-30 | CA$17.76 Million ≈ $12.85 Million |
CA$-14.48 Million ≈ $-10.47 Million |
-0.815x | +80.61% |
| 2020-11-30 | CA$3.22 Million ≈ $2.33 Million |
CA$-13.55 Million ≈ $-9.80 Million |
-4.204x | -2978.87% |
| 2019-11-30 | CA$24.83 Million ≈ $17.96 Million |
CA$-3.39 Million ≈ $-2.45 Million |
-0.137x | -1331.40% |
| 2018-11-30 | CA$35.05 Million ≈ $25.36 Million |
CA$-334.40K ≈ $-241.90K |
-0.010x | -116.76% |
| 2017-11-30 | CA$33.51 Million ≈ $24.24 Million |
CA$1.91 Million ≈ $1.38 Million |
0.057x | -43.11% |
| 2016-11-30 | CA$20.02 Million ≈ $14.48 Million |
CA$2.00 Million ≈ $1.45 Million |
0.100x | -71.72% |
| 2015-11-30 | CA$14.98 Million ≈ $10.83 Million |
CA$5.30 Million ≈ $3.83 Million |
0.354x | +134.63% |
| 2014-11-30 | CA$6.87 Million ≈ $4.97 Million |
CA$-7.02 Million ≈ $-5.08 Million |
-1.022x | -144.46% |
| 2013-11-30 | CA$17.45 Million ≈ $12.62 Million |
CA$-7.29 Million ≈ $-5.28 Million |
-0.418x | +39.39% |
| 2012-11-30 | CA$22.82 Million ≈ $16.51 Million |
CA$-15.74 Million ≈ $-11.39 Million |
-0.690x | +7.92% |
| 2011-11-30 | CA$35.20 Million ≈ $25.46 Million |
CA$-26.36 Million ≈ $-19.07 Million |
-0.749x | -1459.83% |
| 2010-11-30 | CA$51.65 Million ≈ $37.36 Million |
CA$2.84 Million ≈ $2.06 Million |
0.055x | -58.09% |
| 2009-11-30 | CA$40.70 Million ≈ $29.44 Million |
CA$5.35 Million ≈ $3.87 Million |
0.131x | +114.60% |
| 2008-11-30 | CA$37.80 Million ≈ $27.35 Million |
CA$-34.03 Million ≈ $-24.62 Million |
-0.900x | -83.28% |
| 2007-11-30 | CA$65.94 Million ≈ $47.70 Million |
CA$-32.39 Million ≈ $-23.43 Million |
-0.491x | +5.50% |
| 2006-11-30 | CA$38.96 Million ≈ $28.18 Million |
CA$-20.25 Million ≈ $-14.65 Million |
-0.520x | -487.37% |
| 2005-11-30 | CA$41.96 Million ≈ $30.35 Million |
CA$-3.71 Million ≈ $-2.69 Million |
-0.088x | +74.68% |
| 2004-11-30 | CA$53.02 Million ≈ $38.35 Million |
CA$-18.53 Million ≈ $-13.40 Million |
-0.349x | -6.85% |
| 2003-11-30 | CA$64.48 Million ≈ $46.65 Million |
CA$-21.09 Million ≈ $-15.26 Million |
-0.327x | -72.10% |
| 2002-11-30 | CA$79.51 Million ≈ $57.52 Million |
CA$-15.11 Million ≈ $-10.93 Million |
-0.190x | -58.13% |
| 2001-11-30 | CA$70.95 Million ≈ $51.32 Million |
CA$-8.53 Million ≈ $-6.17 Million |
-0.120x | -1.33% |
| 2000-11-30 | CA$38.53 Million ≈ $27.87 Million |
CA$-4.57 Million ≈ $-3.31 Million |
-0.119x | +40.93% |
| 1999-11-30 | CA$16.91 Million ≈ $12.23 Million |
CA$-3.40 Million ≈ $-2.46 Million |
-0.201x | +38.66% |
| 1998-11-30 | CA$10.94 Million ≈ $7.91 Million |
CA$-3.58 Million ≈ $-2.59 Million |
-0.327x | +35.81% |
| 1997-11-30 | CA$7.03 Million ≈ $5.08 Million |
CA$-3.58 Million ≈ $-2.59 Million |
-0.510x | -102.72% |
| 1996-11-30 | CA$11.80 Million ≈ $8.54 Million |
CA$-2.97 Million ≈ $-2.15 Million |
-0.252x | -- |
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more